Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) (NCT06433219)
An Open-label, Multicenter, Randomized Phase 2 Study of the ATR Inhibitor Tuvusertib in Combination With the PARP Inhibitor Niraparib or the ATM Inhibitor Lartesertib in Participants With BRCA Mutant and/or Homologous Recombination deficiency (HRD)-Positive Epithelial Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy (DDRiver EOC 302)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to measure the effect and safety of treatment with tuvusertib combined with either niraparib or lartesertib in participants with epithelial ovarian cancer and to assess any differences between tuvusertib monotherapy and combination therapy. The participants will previously have progressed while treated with a poly ADP ribose polymerase (PARP) inhibitor. The primary objectives of this study are to assess the effect of the treatment in terms of overall response, i.e. whether the tumor disappears, shrinks, remains unchanged, or gets worse and safety in terms of adverse events.
Who can join: Review the eligibility criteria below.
Location: University of Arkansas for Medical Sciences — Little Rock, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (84 Sites)
Showing the first 25 of 84 sites.
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- University of California San Francisco - UCSF Medical Center — San Francisco, California
- Centricity Research Cancer Center - DBA CRRI John B. Amos Cancer Center Research — Columbus, Georgia
- University of Chicago Comprehensive Cancer Center at Silver Cross - Carolyn J. Czerkies Pavilion — Chicago, Illinois
- University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
- Memorial Sloan Kettering Cancer Center — New York, New York
- Icahn School of Medicine at Mount Sinai PRIME - Mount Sinai - PRIME — New York, New York
- Next Oncology - Virginia — Fairfax, Virginia
- Virginia Cancer Specialists, PC — Fairfax, Virginia
- Chris O'Brien Lifehouse — Camperdown,
- St George Private Hospital — Kogarah,
- Liverpool Hospital - PARENT — Liverpool,
- Cliniques Universitaires Saint-Luc - STL — Brussels,
- UZ Leuven — Leuven,
- Ålborg Universitets Hospital - PARENT — Aalborg,
- Rigshospitalet — Copenhagen,
- Sjaellands Universitetshospital - other — Odense,
- ICO - Site Paul Papin - service d'oncologie medicale — Angers,
- Centre Francois Baclesse - Service d'Oncologie Medicale — Caen,
- Centre Oscar Lambret - service de cancerologie gynecologique — Lille,
- Centre Leon Berard - Service d'Oncologie Medicale — Lyon,
- Groupe Hospitalier Diaconesses - Hôpital De La Croix Saint Simon - service d'oncologie medicale — Paris,
- Hopital Tenon - service d'oncologie medicale — Paris,
- Hôpital Cochin - Hematologie et Oncologie Médicale — Paris,
- Hôpital Européen Georges Pompidou - Hématologie Oncologie — Paris,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovarian Cancer
- Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy — New York, New York
- Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer — Pittsburgh, Pennsylvania
- Trial on Radical Upfront Surgery in Advanced Ovarian Cancer — New York, New York
- Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) — Duarte, California
- NeoVax With Nivolumab in Patients With Ovarian Cancer — Boston, Massachusetts
Explore by condition: All Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.